Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,205.7
-12.5 (-0.39%)

 

  • STI Straits Times Index
    3,205.7
    -12.5 (-0.39%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,572.1
    -10.9 (-0.69%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    25,608.5
    -20.2 (-0.08%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,529.0
    -33.3 (-0.93%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    28,802.3
    -296.0 (-1.02%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,528.1
    -74.1 (-1.12%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 868.5M
  • Value: 494.5M
  • Rise: 82
  • Fall: 176
  • Unch: 493

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Raffles Edu0.081+0.014
Tritech0.028-0.001
Geo Energy Res0.335-0.050
Beverly JCG0.001-
Shen Yao0.003-
Rex Intl0.330-0.020
Jiutian Chemical0.087-0.002
Oceanus0.041+0.001
Hatten Land0.059-0.001
Metal Component0.061-0.001

World Indices

World Indices
Name Last Change
Nasdaq 15,235.8 +0.1
HSI 25,608.5 -20.2
HSCEI 9,063.1 -30.7
Jakarta 6,535.1 -67.1
Nikkei 225 28,823.3 -274.9
SSE Comp 3,529.0 -33.3
Shanghai A 3,698.6 -34.8
Shanghai B 270.5 -5.6
KOSPI 3,032.2 +6.7

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

CRESO PHARMA LTD CRESO PHARMA
Updated on 27 Oct 2021 (End of trading day)
Last (AUD): 0.115 Change: - High: 0.120 Remarks: -
Change (%): - Low: 0.115
Open 0.115 Yesterday's Close 0.115
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 7,186,567 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (AUD) a -0.02551 Trailing EPS (AUD) e -0.02680 NAV (AUD) b 0.0222
PE a - Trailing PE f - Price / NAV b 5.1802
Dividend (AUD) d - Cash In Hand (AUD) g 0.0113 Issued & Paid-up Shares c 1,206,530,000
Dividend Yield (%) d - Price / Cash In Hand g 10.177 Treasury Shares h -
Beta - 75 Daysi 2.320 R-Squared - 75 Days(%)i 3.86 Market Cap (M) 138.751
Beta - 500 Daysi 0.659 R-Squared - 500 Days (%)i 0.89 Enterprise Value (M) 125.097
Piotroski F Score 2 Exchange Code CPH Par Value ( AUD ) n.a.
52 Weeks Volatility (%) 164.68 Free Float (%) 79.9
Sector & Industry Health Technology - Pharmaceuticals: Major
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. The figure pertains to the respective exchange the stock is listed on. Updated on 27 Oct 2021.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 21 Oct 2016.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference CRESO PHARMA LTD ASX 138.751 - - 5.1802 -
Industry Pharmaceuticals: Major ASX 134.003 - - 7.1453 -
Local Peer RACE ONCOLOGY LTD ASX 471.875 - - 34.4017 -
Local Peer PYC THERAPEUTICS LIMITED ASX 445.330 - - 8.3832 -
Local Peer STARPHARMA HOLDINGS LIMITED ASX 426.550 - - 6.8449 -
Local Peer AFT PHARMACEUTICALS LTD ASX 408.287 57.573 57.577 12.1344 -
Local Peer RECCE PHARMACEUTICALS LTD ASX 167.696 - - 8.1780 -
Local Peer NOXOPHARM LTD ASX 160.731 - - 3.9427 -
Local Peer EXOPHARM LTD ASX 84.894 - - 4.5000 -
Local Peer INVION LTD ASX 76.243 - - 16.2500 -
Local Peer PALLA PHARMA LTD ASX 57.479 - - 2.8652 -
Local Peer MEDLAB CLINICAL LIMITED ASX 54.748 - - 3.6117 -
Local Peer PHARMAXIS ASX 56.791 - - 19.8413 -
Local Peer ONCOSIL MEDICAL LIMITED ASX 41.202 - - 3.5135 -
Other Local Peers ACRUX (ASX), IMMURON LIMITED (ASX), TALI DIGITAL LIMITED (ASX), ISLAND PHARMACEUTICALS LTD (ASX), AROVELLA THERAPEUTICS LTD (ASX), FIJI KAVA LTD (ASX), FARMAFORCE LTD (ASX)
Global Peer JOHNSON & JOHNSON NYSE 431,042.275 29.295 24.108 - 2.431
Global Peer PFIZER INC NYSE 240,919.469 25.054 18.213 3.4396 3.535
Global Peer ELI LILLY AND COMPANY NYSE 239,307.869 38.637 39.420 37.1343 1.183
Global Peer MERCK & CO INC NYSE 206,407.910 29.207 37.050 6.1995 3.040
Global Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 201,399.567 24.950 22.418 3.7267 2.330
Global Peer ABBVIE INC NYSE 191,562.312 42.046 29.073 15.2408 4.460
Global Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NASDAQ 191,380.138 59.881 50.751 12.2085 1.879
Global Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 187,324.141 29.070 26.313 17.9170 1.273
Global Peer BRISTOL-MYERS SQUIBB CO NYSE 125,526.994 - - 3.4103 3.289
Global Peer SANOFI SPON ADR ECH REP 0.5 ORD SHS NASDAQ 125,260.416 8.923 18.088 1.6703 -
Other Global Peers GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 (NYSE), WUXI APPTEC CO LTD (HKEx), TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS (NYSE), ROYALTY PHARMA PLC (NASDAQ), VIATRIS INC (NASDAQ), REPLIGEN CORP (NASDAQ), HANSOH PHARMACEUTICAL GROUP CO LTD (HKEx), INNOVENT BIOLOGICS INC (HKEx), ORGANON & CO (NYSE), BIOHAVEN PHARMACEUTICAL HLDG CO LTD (NYSE), CANSINO BIOLOGICS INC (HKEx), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS (NASDAQ), SINOPHARM GROUP CO. LTD. (HKEx), CUREVAC NV (NASDAQ), REMEGEN CO LTD (HKEx), ALLAKOS INC (NASDAQ), CEREVEL THERAPEUTICS HLDGS INC (NASDAQ), HUTCHMED (CHINA) LIMITED SPON ADS EACH REPR 5 ORD SHS (NASDAQ), HYGEIA HEALTHCARE HLDGS CO LTD (HKEx), HUTCHMED (CHINA) LIMITED (HKEx), SHANGHAI PHARMACEUTICALS HOLDING CO (HKEx), I MAB SPON ADS EACH REP 2.3 ORD SHS (NASDAQ), AKESO INC (HKEx), SHANGHAI JUNSHI BIOSCIENCES CO LTD (HKEx), CHINA MEDICAL SYSTEM HLDGS LTD (HKEx), GUANGZHOU BAIYUNSHAN PHARMACEUTICAL (HKEx), KARUNA THERAPEUTICS INC (NASDAQ), INNOCARE PHARMA LTD (HKEx), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), REATA PHARMACEUTICALS INC (NASDAQ), IMMUNITYBIO INC (NASDAQ), SPRINGWORKS THERAPEUTICS INC (NASDAQ), CHINA RESOURCES PHARMACEUTICAL GR (HKEx), CARSGEN THERAPEUTICS HLDGS LTD (HKEx), NEKTAR THERAPEUTICS (NASDAQ), CHINA GRAND PHARMACEUTICAL & HEALTH (HKEx), APELLIS PHARMACEUTICALS INC (NASDAQ), SIMCERE PHARMACEUTICAL GRP LTD (HKEx), EMERGENT BIOSOLUTIONS INC (NYSE), OPKO HEALTH INC (NASDAQ), ERASCA INC (NASDAQ), HARMONY BIOSCIENCES HLDGS INC (NASDAQ), CHINA TRADITIONAL CHINESE MED HLDGS (HKEx), ATAI LIFE SCIENCES NV (NASDAQ), ADC THERAPEUTICS SA (NYSE), TURNING POINT THERAPEUTICS INC (NASDAQ), QUANTERIX CORPORATION (NASDAQ), SHANGHAI HENLIUS BIOTECH INC (HKEx), EVEREST MEDICINES LTD (HKEx), DICERNA PHARMACEUTICALS INC. (NASDAQ), AMNEAL PHARMACEUTICALS INC (NYSE), IGM BIOSCIENCES INC (NASDAQ), SHENZHEN HEPALINK PHARMACEUTICAL (HKEx), DAY ONE BIOPHARMACEUTICALS INC (NASDAQ), CENTESSA PHARMACEUTICALS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), SSY GROUP LIMITED (HKEx), CSTONE PHARMACEUTICALS (HKEx), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), OCUMENSION THERAPEUTICS (HKEx), NURIX THERAPEUTICS INC (NASDAQ), GENERATION BIO CO (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), UNITED LABORATORIES INTL HLDGS LTD (HKEx), Y-MABS THERAPEUTICS INC (NASDAQ), PROCAPS GROUP S A (NASDAQ), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), ZYMEWORKS INC (NYSE), IMMUNOTECH BIOPHARM LTD (HKEx), OLEMA PHARMACEUTICALS INC (NASDAQ), BEIJING TONG REN TANG CHINESE MEDIC (HKEx), KINNATE BIOPHARMA INC (NASDAQ), ICOSAVAX INC (NASDAQ), ATEA PHARMACEUTICALS INC (NASDAQ), Kimia Farma Tbk. (IDX), ABBISKO CAYMAN LTD (HKEx), TENAYA THERAPEUTICS INC (NASDAQ), PRAXIS PRECISION MEDICINES INC (NASDAQ), PHATHOM PHARMACEUTICALS INC (NASDAQ), CONNECT BIOPHARMA HLDGS LTD ADS EACH REP ONE ORD SHARE (NASDAQ), GOSSAMER BIO INC (NASDAQ), KRONOS BIO INC (NASDAQ), SCICLONE PHARMACEUTICALS (HLDGS) LT (HKEx), CULLINAN ONCOLOGY INC (NASDAQ), KEROS THERAPEUTICS INC (NASDAQ), FULCRUM THERAPEUTICS INC (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), CK LIFE SCIENCES INTL HLDG (HKEx), SUTRO BIOPHARMA INC (NASDAQ), FORMA THERAPEUTICS HLDGS INC (NASDAQ), REPARE THERAPEUTICS INC (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), ANTENGENE CORP LTD (HKEx), MIND MEDICINE (MINDMED) INC (NASDAQ), GH RESEARCH PLC (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), POINT BIOPHARMA GLOBAL INC (NASDAQ), PETIQ INC (NASDAQ), CHINA SHINEWAY PHARMACEUTICAL GR (HKEx), ALIGOS THERAPEUTICS INC (NASDAQ), AMRYT PHARMA PLC (NEW) SPON ADS EACH REP 5 ORD SHS (NASDAQ), ANNEXON INC (NASDAQ), GRITSTONE BIO INC (NASDAQ), VERU INC (NASDAQ), ALPHA TEKNOVA INC (NASDAQ), TALARIS THERAPEUTICS INC (NASDAQ), ACUMEN PHARMACEUTICALS INC (NASDAQ), TARSUS PHARMACEUTICALS INC (NASDAQ), BEYONDSPRING INC (NASDAQ), TRANSCENTA HOLDING LTD (HKEx), G1 THERAPEUTICS IN (NASDAQ), ORIC PHARMACEUTICALS INC (NASDAQ), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), SIGA TECHNOLOGIES INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), NRX PHARMACEUTICALS INC (NASDAQ), PHARVARIS NV (NASDAQ), ADAGENE INC SPON ADS EACH REP 1.25 ORD SHS (NASDAQ), HUA MEDICINE (HKEx), Soho Global Health Tbk. (IDX), MIRUM PHARMACEUTICALS INC (NASDAQ), VACCITECH PLC ADR EACH REPR 1 ORD SH SPON (NASDAQ), CHINOOK THERAPEUTICS INC (NASDAQ), BOLT BIOTHERAPEUTICS INC (NASDAQ), ZHAOKE OPHTHALMOLOGY LTD (HKEx), AC IMMUNE SA (NASDAQ), BROOKLYN IMMUNO THERAPEUTICS INC (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), EVOLUS INC (NASDAQ), IGBB (Bursa), WEREWOLF THERAPEUTICS INC (NASDAQ), PYXIS ONCOLOGY INC (NASDAQ), NANOBIOTIX S A SPON ADS EACH REP 1 ORD SHS (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), MINK THERAPEUTICS INC (NASDAQ), KALVISTA PHARMACEUTICALS INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), ESSA PHARMA INC (NASDAQ), PROVENTION BIO INC (NASDAQ), VERRICA PHARMACEUTICALS INC (NASDAQ), 89BIO INC (NASDAQ), CLENE INC (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), CODIAK BIOSCIENCES INC (NASDAQ), DAWNRAYS PHARMACEUTICAL HLDGS (HKEx), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), THERATECHNOLOGIES INC (NASDAQ), TOT BIOPHARM INTL CO LTD (HKEx), SILVERBACK THERAPEUTICS INC (NASDAQ), CYBIN INC (NYSE American), CLEARSIDE BIOMEDICAL INC (NASDAQ), BIOMEA FUSION INC (NASDAQ), FUSION PHARMACEUTICALS INC (NASDAQ), BSTEAD (Bursa), OYSTER POINT PHARMA INC (NASDAQ), NEXIMMUNE INC (NASDAQ), CITIUS PHARMACEUTICALS INC (NASDAQ), ATHENEX INC (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), XOMA CORP (NASDAQ), ACHILLES THERAPEUTICS PLC ADS EACH REPR 1 SHARE SPON (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), HARROW HEALTH INC (NASDAQ), FUSEN PHARMACEUTICAL CO LTD (HKEx), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), ANGION BIOMEDICA CORP (NASDAQ), PHARMA (Bursa), DURECT CORP (NASDAQ), TCR2 THERAPEUTICS INC (NASDAQ), VINCERX PHARMA INC (NASDAQ), OVID THERAPEUTICS INC (NASDAQ), TRICIDA INC (NASDAQ), GAMIDA CELL LTD (NASDAQ), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), IMPEL NEUROPHARMA INC (NASDAQ), IMMUNIC INC (NASDAQ), OBSEVA SA (NASDAQ), ANNOVIS BIO INC (NYSE American), INOZYME PHARMA INC (NASDAQ), MUSTANG BIO INC (NASDAQ), SOL GEL TECHNOLOGIES LTD (NASDAQ), VECTIVBIO HLDG AG (NASDAQ), IP (SET), TFF PHARMACEUTICALS INC (NASDAQ), REGENCELL BIOSCIENCE HLDGS LTD (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), LIQUIDIA CORPORATION (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), ALZAMEND NEURO INC (NASDAQ), PHASEBIO PHARMACEUTICALS INC (NASDAQ), ONCTERNAL THERAPEUTICS INC (NASDAQ), KALEIDO BIOSCIENCES INC (NASDAQ), 180 LIFE SCIENCES CORP (NASDAQ), SATSUMA PHARMACEUTICALS INC (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), RENEO PHARMACEUTICALS INC (NASDAQ), ANEBULO PHARMACEUTICALS INC (NASDAQ), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), 4D PHARMA PLC SPONS ADR EACH REP 8 ORD SHS (NASDAQ), CHINA BIOTECH SERVICES HLDGS LTD (HKEx), HOOKIPA PHARMA INC (NASDAQ), F-STAR THERAPEUTICS INC (NASDAQ), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), ORPHAZYME A/S SPON ADS REP 1 ORD SHS (NASDAQ), IX Biopharma (SGX), QILIAN INTERNATIONAL HLDG GROUP LTD (NASDAQ), AYALA PHARMACEUTICALS INC (NASDAQ), POLYPID LTD (NASDAQ), NOVAN INC (NASDAQ), NEUBASE THERAPEUTICS INC (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), LANTERN PHARMA INC (NASDAQ), ODONATE THERAPEUTICS INC (NASDAQ), ZHONGZHI PHARMACEUTICAL HLDGS LTD (HKEx), VTV THERAPEUTICS INC (NASDAQ), ENTERA BIO LTD (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), Merck Tbk. (IDX), KALA PHARMACEUTICALS INC (NASDAQ), APREA THERAPEUTICS INC (NASDAQ), LANNETT CO INC (NYSE), KOTRA (Bursa), EDESA BIOTECH INC (NASDAQ), EYENOVIA INC (NASDAQ), MEDIWOUND LTD (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), LYRA THERAPEUTICS INC (NASDAQ), GENPREX INC (NASDAQ), IMARA INC (NASDAQ), CHARMACY PHARMACEUTICAL CO LTD (HKEx), CLARUS THERAPEUTICS HLDGS INC (NASDAQ), NEW RAY MEDICINE INTL HLDG LTD (HKEx), YUMANITY THERAPEUTICS INC (NASDAQ), PROPHASE LABS INC (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), GALECTO INC (NASDAQ), AILERON THERAPEUTICS INC (NASDAQ), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), TEMPEST THERAPEUTICS INC (NASDAQ), PURPLE BIOTECH LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), MANNATECH INC (NASDAQ), MOLECULIN BIOTECH INC (NASDAQ), PROTARA THERAPEUTICS INC (NASDAQ), Phapros Tbk. (IDX), ELEDON PHARMACEUTICALS INC (NASDAQ), VYNE THERAPEUTICS INC (NASDAQ), OCUPHIRE PHARMA INC (NASDAQ), ALLENA PHARMACEUTICALS INC (NASDAQ), GRAYBUG VISION INC (NASDAQ), ADIAL PHARMACEUTICALS INC (NASDAQ), Hyphens Pharma (SGX), NOVA (Bursa), PAK FAH YEOW INTERNATIONAL (HKEx), NEW CENTURY HEALTHCARE HLDGS CO LTD (HKEx), AYTU BIOPHARMA INC (NASDAQ), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS (NASDAQ), ABVC BIOPHARMA INC (NASDAQ), SYNAPTOGENIX INC (NASDAQ), SANAI HEALTH INDUSTRY GP CO LTD (HKEx), BIOHLDG (Bursa), WAI YUEN TONG MEDICINE HOLDINGS LTD (HKEx), ACURX PHARMACEUTICALS INC (NASDAQ), MODERN CHINESE MEDICINE GRP CO LTD (HKEx), SHENZHEN NEPTUNUS INTERLONG BIO-TEC (HKEx), UNIVERSE PHARMACEUTICALS INC (NASDAQ), INHIBIKASE THERAPEUTICS INC (NASDAQ), VIRPAX PHARMA INC (NASDAQ), GALERA THERAPEUTICS INC (NASDAQ), BONE BIOLOGICS CORP (NASDAQ), RENOVORX INC (NASDAQ), REVIVA PHARMACEUTICALS HOLDINGS INC (NASDAQ), SEQLL INC (NASDAQ), BAUDAX BIO INC (NASDAQ), ASSERTIO HOLDINGS INC (NASDAQ), BRICKELL BIOTECH INC (NASDAQ), PURAPHARM CORPORATION LIMITED (HKEx), ARIDIS PHARMACEUTICAL INC (NASDAQ), CNS PHARMACEUTICALS INC (NASDAQ), DERMATA THERAPEUTICS INC (NASDAQ), VIRIOS THERAPEUTICS INC (NASDAQ), PASITHEA THERAPEUTICS CORP (NASDAQ), ACER THERAPEUTICS INC (NASDAQ), AGEX THERAPEUTICS INC (NYSE American), XORTX THERAPEUTICS INC (NASDAQ), VALLON PHARMACEUTICALS INC (NASDAQ), JCT (SET), EXTRAWELL PHARMACEUTICAL HLDGS (HKEx), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), SUNZEN (Bursa), TIMBER PHARMACEUTICALS INC (NYSE American), NLS PHARMACEUTICS LTD (NASDAQ), PANBELA THERAPEUTICS INC (NASDAQ), TREVI THERAPEUTICS INC (NASDAQ), AVENUE THERAPEUTICS INC (NASDAQ), HOTH THERAPEUTICS INC (NASDAQ), PAINREFORM LTD (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), PETROS PHARMACEUTICALS INC (NASDAQ), NANJING SINOLIFE UNITED COMPANY LTD (HKEx), TITAN PHARMACEUTICAL INC (NASDAQ), CHINA SXT PHARMACEUTICALS INC (NASDAQ), PA SHUN INTERNATIONAL HOLDINGS LTD (HKEx), Pharmesis Intl (SGX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+0.005
+4.55 %
10 Days -+0.005
+4.55 %
20 Days -+0.005
+4.55 %
Medium Term Return 3 Months -+0.005
+4.55 %
6 Months --0.085
-42.50 %
1 Year -+0.088
+325.93 %
Long Term Return 2 Years --0.090
-43.90 %
3 Years --0.300
-72.29 %
5 Years --0.140
-54.90 %
Annualised Return Annualised --
-14.72 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.024 - 0.470 Change From 1 Year Low +0.091 % Change From 1 Year Low (%) +379.17
Change From 1 Year High -0.355 % Change From 1 Year High (%) -75.53
2 Years Range 0.024 - 0.470 Change From 2 Years Low +0.091 % Change From 2 Years Low (%) +379.17
Change From 2 Years High -0.355 % Change From 2 Years High (%) -75.53
5 Years Range 0.024 - 1.650 Change From 5 Years Low +0.091 % Change From 5 Years Low (%) +379.17
Change From 5 Years High -1.535 % Change From 5 Years High (%) -93.03
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Creso Pharma Ltd. develops, registers and commercializes pharmaceutical-grade cannabis and hemp-based nutraceutical products and treatments. It operates through the following segments: Hemp-Industries s.r.o. in Slovakia, Creso Pharma Switzerland GmbH in Switzerland and Creso Pharma Limited in Australia. The company was founded by Adam Blumenthal, Miri Halperin Wernli and Boaz Wachtel on November 20, 2015 and is headquartered in Barangaroo, Australia.

Historical Price Data

Date Open High Low Close Volume VWAP
27 Oct 2021 0.115 0.120 0.115 0.115 7,186,567 -
26 Oct 2021 0.115 0.125 0.115 0.115 13,364,780 -
25 Oct 2021 0.110 0.125 0.110 0.110 20,024,620 -
22 Oct 2021 0.110 0.115 0.110 0.110 2,349,694 -
21 Oct 2021 0.110 0.115 0.110 0.110 3,037,618 -
20 Oct 2021 0.120 0.120 0.110 0.110 9,620,544 -
19 Oct 2021 0.110 0.115 0.110 0.115 1,443,276 -
18 Oct 2021 0.115 0.115 0.110 0.110 2,740,682 -
15 Oct 2021 0.115 0.115 0.110 0.110 2,241,097 -
14 Oct 2021 0.110 0.115 0.110 0.115 2,187,371 -
13 Oct 2021 0.115 0.115 0.110 0.110 822,454 -
12 Oct 2021 0.115 0.115 0.110 0.110 1,530,618 -
11 Oct 2021 0.115 0.120 0.110 0.110 2,696,654 -
08 Oct 2021 0.115 0.120 0.115 0.115 6,612,117 -
07 Oct 2021 0.110 0.115 0.110 0.110 1,418,371 -
06 Oct 2021 0.100 0.115 0.100 0.110 9,226,268 -
05 Oct 2021 0.110 0.120 0.100 0.100 25,165,380 -
04 Oct 2021 0.110 0.115 0.105 0.105 2,965,487 -
01 Oct 2021 0.110 0.110 0.105 0.110 1,525,042 -
30 Sep 2021 0.110 0.115 0.105 0.110 11,588,000 -
29 Sep 2021 0.110 0.115 0.110 0.110 4,087,125 -
28 Sep 2021 0.110 0.115 0.110 0.110 9,069,226 -
Summary
Current 2 Weeks
(14 Oct 2021 to 27 Oct 2021)
0.110 0.125 0.110 0.115 64,196,249 -
Previous 2 Weeks
(30 Sep 2021 to 13 Oct 2021)
0.110 0.125 0.105 0.110 63,550,391 -
4 Weeks from
(02 Sep 2021 to 29 Sep 2021)
0.130 0.135 0.110 0.110 92,195,545 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.